Our novel findings clarify a link between oncogenic YAP and radioresistance, suggesting that the inhibitors of the YAP–FGF2–MAPK pathway may have therapeutic value for patients with high YAP expression by restoring radiosensitivity and inducing glioma cell death after radiation. This evidence concerns the gene FGF2 and central nervous system cancer.